Question 1

What is CMC submission software?

Accepted Answer

CMC submission software supports the Chemistry, Manufacturing, and Controls workflow inside regulatory submissions: Module 3 authoring, analytical method documentation, stability data summaries, process descriptions, specifications, and comparability analysis. Unlike general submission software, CMC-focused tools understand the structural requirements of Module 3 (ICH Q1-Q14, FDA CMC guidance, EMA quality guidelines) and coordinate the cross-functional work across Manufacturing Sciences, Quality Control, Process Development, and Regulatory Affairs. It's the most specialized submission workflow in pharma because Module 3 drives more review time than any other module.

Question 2

How does Assyro handle CDMO-contributed Module 3 content?

Accepted Answer

CDMO partners receive scoped access to their assigned Module 3 sections in the sponsor workspace. For a sponsor using a CDMO for drug substance manufacture, the CDMO authors sections 3.2.S.2 (Manufacture), 3.2.S.3 (Characterization), 3.2.S.4 (Controls), and 3.2.S.7 (Stability) directly in the sponsor's submission workspace without gaining access to the sponsor's clinical data. The pattern replaces the email-and-FTP CDMO collaboration that most sponsor-CDMO relationships still run, with a 3-5x reduction in coordination time per submission.

Question 3

What ICH guidelines does Assyro align with?

Accepted Answer

Full coverage of the ICH Quality series: Q1 (stability), Q2 (analytical validation), Q3 (impurities), Q4 (pharmacopoeias), Q5 (biologics quality), Q6 (specifications), Q7 (GMP), Q8 (pharmaceutical development), Q9 (quality risk management), Q10 (quality system), Q11 (drug substance development), Q12 (lifecycle management), Q13 (continuous manufacturing), and Q14 (analytical development). Templates and validation rules update as ICH publishes new guidelines or finalizations of workstream documents.

Question 4

Does Assyro help with post-approval changes and supplements?

Accepted Answer

Yes. Post-approval CMC changes are categorized into Annual Reports (minor, reportable), CBE-30 (moderate, 30-day notification), CBE-0 (minor-moderate, immediate), and Prior Approval Supplements (major, requires FDA approval before implementation). Assyro's change classification tool reviews proposed changes against FDA's change-control categories and recommends the appropriate filing type with rationale. Drafting the supplement itself uses the same authoring workflow as original submissions, which accelerates post-approval change velocity significantly.

Question 5

How does Assyro handle comparability across process changes?

Accepted Answer

When a CMC change affects drug substance or drug product, regulators expect comparability analysis showing the post-change material is equivalent to the pre-change material across identity, purity, potency, and stability. Assyro structures comparability evidence (characterization data, impurity profiles, stability comparisons, bioassay results) against the change being made, and flags when additional comparability work is needed for regulatory acceptance. This matters because inadequate comparability is one of the most common CMC review deficiencies.

Question 6

Is Assyro suitable for biologics CMC versus small-molecule CMC?

Accepted Answer

Yes for both. Biologics CMC (recombinant proteins, monoclonal antibodies, cell therapies, gene therapies) has different content expectations than small-molecule CMC: more extensive characterization, comparability across process changes, adventitious agents safety, and for cell/gene therapy, CBER-specific considerations. Assyro's Module 3 structure supports biologics-specific content through ICH Q5A-Q5E alignment and CBER guidance templates. Small-molecule CMC is handled through the standard ICH Q series structure. Teams working across both modalities (common in diversified biotech) can use the same platform.

Question 7

Can CMC teams collaborate with Manufacturing and QC in Assyro?

Accepted Answer

Yes. CMC submission work pulls evidence from Manufacturing (batch records, process validation, equipment qualification), QC (analytical method validation, release testing, stability data), and Quality Systems (change control, deviations, CAPA). Assyro integrates with common operational systems (Veeva QualityOne, Master Control, internal LIMS) so the submission content links back to live operational evidence. When an FDA question references specific batch data in Module 3.2.P.3, the linked operational record is retrievable for inspection response.

Question 8

Does Assyro support ICH Q12 lifecycle management and PACMP?

Accepted Answer

Yes. ICH Q12 introduced the concept of Established Conditions (ECs) and Post-Approval Change Management Protocols (PACMPs) to streamline post-approval CMC change management. Assyro supports EC documentation, PACMP authoring, and the linkage from PACMP-covered changes to their expedited regulatory pathway. For sponsors adopting ICH Q12 lifecycle strategies, this capability reduces the post-approval change cycle time significantly by moving changes from Prior Approval Supplements into PACMP-covered annual reports where appropriate.

CMC Submission Software

CMC Workflow Coverage

Keep Module 3 Packages Aligned From First Draft

Coordinate CDMO-Contributed Content Without the FTP Dance

Manage Comparability Data Across Process Changes

Draft Post-Approval Change Filings in Days, Not Weeks

CMC Controls and Capacity

Maintain Audit-Ready Team Execution

Manage More CMC Work Without Growing the Team

Questions About CMC Workflows

See CMC Workflows in Assyro.